Tumor-infiltrating myeloid cells can promote tumor progression through surface expression of immune checkpoint molecules such as PD-L1 and by production of anti-inflammatory cytokines that induce immune suppression and resistance to checkpoint inhibition33–35. This evidence concerns the gene CD274 and neoplasm.